Detection of West Nile virus in the Mexican blood supply

被引:11
作者
Sánchez-Guerrero, SA
Romero-Estrella, S
Rodríguez-Ruiz, A
Infante-Ramírez, L
Gómez, A
Villanueva-Vidales, E
García-Torres, M
Domínguez, AMA
Vázquez, JA
Calderón, ED
Valiente-Banuet, L
Linnen, JM
Broulik, A
Harel, W
López, RAMY
机构
[1] Natl Ctr Blood Transfus, Mexico City, DF, Mexico
[2] Gen Probe Inc, San Diego, CA USA
[3] Chiron Blood Testing Corp, Emeryville, CA USA
关键词
D O I
10.1111/j.1537-2995.2006.00666.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: West Nile virus (WNV) is the etiologic agent of an emerging disease in the Western Hemisphere that can be transmitted to humans by blood transfusion. WNV first appeared in the United States in 1999, in Canada in 2001, and in Mexico in 2002. The aim of this nationwide study was to determine the prevalence of WNV in blood donors in Mexico as a first step in preventing its transfusion-associated transmission. STUDY DESIGN AND METHODS: In July and August 2004, a total of 3856 fresh plasma specimens collected from each state's center for blood transfusion in 29 of 31 Mexican states were screened with an investigational WNV assay (Procleix,(R) Gen-Probe Inc. and Chiron Corp.), a nucleic acid test based on transcription-mediated amplification (TMA). Reactive specimens were confirmed with a second TMA-based test, the alternative WNV assay (Gen-Probe), and with WNV capture enzyme-linked immunosorbent assays (ELISAs) for detection of immunoglobulin M (IgM) and IgG antibodies. In addition, 3714 frozen plasma samples collected in 2002 and 2003 were similarly tested. RESULTS: One of 3856 fresh samples from an asymptomatic donor from Chihuahua was reactive by both TMA-based tests and IgM ELISA, suggesting a recently acquired infection. The observed percentage of viremic donors blood donors was 0.03 percent. Results from frozen samples were not included in the prevalence calculation and none were TMA-reactive for WNV. CONCLUSIONS: WNV is present in the Mexican blood supply and measures should be taken to reduce the risk of transfusion transmission.
引用
收藏
页码:111 / 117
页数:7
相关论文
共 42 条
[1]  
Aguzzi A, 2004, J CLIN INVEST, V114, P153, DOI [10.1172/JCI200422438, 10.1172/JCI22438]
[2]  
Blitvich BJ, 2004, EMERG INFECT DIS, V10, P1314
[3]  
Blitvich BJ, 2003, EMERG INFECT DIS, V9, P853
[4]   Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003 [J].
Busch, MP ;
Tobler, LH ;
Saldanha, J ;
Caglioti, S ;
Shyamala, V ;
Linnen, JM ;
Gallarda, J ;
Phelps, B ;
Smith, RIF ;
Drebot, M ;
Kleinman, SH .
TRANSFUSION, 2005, 45 (04) :492-499
[5]  
Caglioti S, 2004, TRANSFUSION, V44, p140A
[6]  
*CDCP, 2004, MMWR-MORBID MORTAL W, V53, P281
[7]  
*CDCP, 2005, 2004 W NIL VIR ACT U
[8]  
*CHIR CORP, 2003, PACK INS PROCL W NIL
[9]  
Cline J, 2004, TRANSFUSION, V44, p138A
[10]  
*CTR BIOL EV RES, 2005, GUID IND ASS DON SUI